Napolitano A, Joensuu H, Rothschild S, Evans D, Heinrich MC, Sutton TL, Mayo SC, Boye K, Falkenhorst J, Le Cesne A, Hohenberger P, Rutkowski P, van Houdt WJ, Steeghs N, Gelderblom H, Desar IME, Pantaleo MA, Nishida T, Reichardt P, Blay JY, Somaiah N, Haddad EFN, Grignani G, Baldi GG, Steigen SE et al. (2026)
Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations
JAMA Oncol (in press)
DOI 10.1001/jamaoncol.2026.0007, PubMed 41746633

Moura DS, Lopez-Marti J, Tawbi H, Keung E, Wani K, Lazar A, Wang WL, Ingram DR, Meza-Zepeda LA, Myklebost O, Burgess M, Mondaza-Hernandez JL, Hindi N, Martín-Broto J (2026)
Validation of a seven-gene predictive SIGNature for the efficacy of Immuno-Oncology PD-1 inhibitors in patients with Sarcoma (SIGNIOS)
Clin Cancer Res (in press)
DOI 10.1158/1078-0432.CCR-25-2580, PubMed 41537707

Heinrich MC, Blay JY, Gelderblom H, George S, Schöffski P, von Mehren M, Zalcberg JR, Jones RL, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Boye K, Goldstein D, Sánchez C, Siontis BL, Cox P, Davis E, Sherman ML, Ruiz-Soto R, Bauer S (2025)
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
J Clin Oncol, 43 (20), 2239-2244
DOI 10.1200/JCO-24-02818, PubMed 40408605